Evidence map›Paper›PMID 30636545›Full record

ArticleJournal of the American Heart Association2019

Lymph Vessel Proliferation on Cardiac Biopsy May Help in the Diagnosis of Cardiac Sarcoidosis.

Yukiko Oe, Hatsue Ishibashi-Ueda, Taka-Aki Matsuyama, Yen-Hong Kuo, Toshiyuki Nagai, Yoshihiko Ikeda, Keiko Ohta-Ogo, Teruo Noguchi, Toshihisa Anzai

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Cardiac sarcoidosis in patients with recurrent ventricular arrhythmias refractory to endocardial ablation.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  3. Article
  4. Review
  5. Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024
    Review
  6. Current uses and understanding of PET imaging in cardiac sarcoidosis.American journal of nuclear medicine and molecular imaging · 2024
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Yukiko Oe1 Division of Pulmonary and Critical Care Medicine and Allergy and Rheumatology Department of Medicine Rutgers New Jersey Medical School Newark NJ.
Hatsue Ishibashi-Ueda2 Department of Pathology National Cerebral and Cardiovascular Center Osaka Japan.
Taka-Aki Matsuyama3 Department of Legal Medicine Showa University School of Medicine Tokyo Japan.
Yen-Hong Kuo4 Biostatistics Core Office of Research Administration Hackensack Meridian Health Neptune NJ.
Toshiyuki Nagai5 Department of Cardiovascular Medicine Hokkaido University Graduate School of Medicine Hokkaido Japan.
Yoshihiko Ikeda2 Department of Pathology National Cerebral and Cardiovascular Center Osaka Japan.
Keiko Ohta-Ogo2 Department of Pathology National Cerebral and Cardiovascular Center Osaka Japan.
Teruo Noguchi6 Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Osaka Japan.
Toshihisa Anzai5 Department of Cardiovascular Medicine Hokkaido University Graduate School of Medicine Hokkaido Japan.
National Cerebral and Cardiovascular Center · JPHackensack Meridian Health · USHokkaido University · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The diagnosis of cardiac sarcoidosis ( CS ) is challenging because endomyocardial biopsy has only a 20% to 30% sensitivity rate for diagnosis and it presents with similar clinical features of idiopathic dilated cardiomyopathy ( DCM ). Lymphatic vessel proliferation in pulmonary sarcoidosis has been previously demonstrated. In this study, we compared endomyocardial biopsy samples obtained from patients with CS and DCM to determine whether lymph vessel counts using D2-40 immunostaining can be utilized as a complementary tool to distinguish CS from DCM . Methods and Results Endomyocardial biopsy tissues were obtained from 62 patients with CS (30 patients with a diagnosis made histologically, 32 patients with a diagnosis made clinically), and hematoxylin/eosin, Masson trichrome, and D2-40 immunostaining were performed. Their results were compared with those from 53 patients with DCM. The histological CS group showed significantly increased lymphatic vessels (12.0 [4.0-40.0] versus 2.6 [1.9-3.4], P<0.0001) and more severe mosaic fibrosis ( P<0.0001) compared with the DCM group. The optimal threshold was 7.5 lymphatic vessels, and this resulted in a sensitivity of 0.67 and specificity of 0.96. The clinical CS group diagnosed according to Japanese Circulation Society 2016 criteria showed increased lymphatic vessels (4.0 [3.3-9.0] versus 2.6 [1.9-3.4], P<0.0001), more severe mosaic fibrosis ( P<0.0001), more inflammatory cell infiltration (53% versus 0%, P<0.0001), and fatty infiltration within fibroblasts (50% versus 17%, P=0.0012) compared with the DCM group. The optimal threshold of lymphatic vessels was 3.5, which resulted in a sensitivity of 0.75 and specificity of 0.68. Conclusions Lymphatic vessel counts using D2-40 immunostaining may help to distinguish clinical CS without granuloma from DCM .

Indexed as

AgedBiopsyCardiomyopathiesCell ProliferationFemaleFollow-Up StudiesHumansLymphatic VesselsMaleMiddle AgedMyocardiumRetrospective StudiesSarcoidosiscardiac sarcoidosisD2‐40 immunostainingendomyocardial biopsylymphatic vessel

Identifiers

PMID30636545
PMCPMC6497329
OpenAlexW2911036255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.